Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn’s Disease: A Retrospective Study From 2 Referral Centers
Inflammatory Bowel Diseases · 2023
DOI: 10.1093/ibd/izac167 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2023. Verfasst von Pauline Rivière und 12 weiteren Autor:innen. Beteiligte Einrichtung: INSERM CIC 1401, Gastroenterology Department, Centre Medico-chirurgical Magellan, Hôpital Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux,…. Hauptthemen laut MEDLINE: Crohn Disease, Biological Products. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Background
Real-life data on the efficacy of ustekinumab as first-line therapy for the treatment of luminal Crohn’s disease (CD) compared with anti-tumor necrosis factor (anti-TNF) agents are lacking. We compared the clinical response rates at 3 months in 2 cohorts of biologic-naïve patients treated by ustekinumab and anti-TNF agents.
Methods
Biologic-naïve patients starting either ustekinumab or an anti-TNF agent for luminal CD between 2016 and 2019 in 2 tertiary centers were retrospectively included. The primary endpoint was clinical response at 3 months, defined as a Harvey-Bradshaw Index <4 or a 3-point drop in the score without steroids, need for CD-related surgery, or treatment discontinuation owing to failure or intolerance. Patients treated with ustekinumab were matched to patients receiving anti-TNF agents by a propensity score algorithm.
Results
We included 156 patients starting anti-TNF agents (95 adalimumab and 61 infliximab) and 50 ustekinumab. After matching, clinical response rates at 3 months were 64% and 86% in the ustekinumab and anti-TNF groups, respectively (P = .01). At 12 months, in multivariate analysis adjusted for disease duration, location, concomitant immunosuppressant and steroids, and symptoms, clinical remission was independently associated with the biological therapy received (odds ratio, 2.6 for anti-TNF agent vs ustekinumab; P = .02). With a median follow-up duration of 40 (interquartile range, 23-52) months, no difference was observed in terms of time to drug withdrawal (P = .29) or safety.
Conclusions
This retrospective real-world data suggest that an anti-TNF agent as a first-line biological therapy is associated with higher rates of response at 3 months than ustekinumab in patients with CD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- INSERM CIC 1401, Gastroenterology Department, Centre Medico-chirurgical Magellan, Hôpital Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, Université de Bordeaux, Bordeaux, France.
- Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Quebec, Canada.
ORCID-Profile: Pauline Rivière, Talat Bessissow
Zitieren
APA
Rivière, P., Kanters, C., Pellet, G., Ni, A., Hupé, M., Aboulhamid, N., Poullenot, F., Bitton, A., Zerbib, F., Lakatos, P. L., Afif, W., Laharie, D., & Bessissow, T. (2023). Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn’s Disease: A Retrospective Study From 2 Referral Centers. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izac167
Vancouver
Rivière P, Kanters C, Pellet G, Ni A, Hupé M, Aboulhamid N, et al. Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn’s Disease: A Retrospective Study From 2 Referral Centers. Inflammatory Bowel Diseases. 2023. doi:10.1093/ibd/izac167
BibTeX
@article{Rivire2023,
author = {Rivière, Pauline and Kanters, Caitlyn and Pellet, Gauthier and Ni, Alexander and Hupé, Marianne and Aboulhamid, Nesrine and Poullenot, Florian and Bitton, Alain and Zerbib, Frank and Lakatos, Peter L and Afif, Waqqas and Laharie, David and Bessissow, Talat},
title = {Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn’s Disease: A Retrospective Study From 2 Referral Centers},
journal = {Inflammatory Bowel Diseases},
year = {2023},
doi = {10.1093/ibd/izac167}
}
EUVIMED